Published in Arch Ophthalmol on April 01, 1989
Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2. Genes Dev (2000) 2.72
Molecular analysis of the NF2 tumor-suppressor gene in schwannomatosis. Am J Hum Genet (1997) 1.96
High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. Proc Natl Acad Sci U S A (1995) 1.76
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet (1996) 1.70
A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. J Med Genet (1992) 1.62
Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet (1996) 1.52
Neurofibromatosis type 2. J Med Genet (2000) 1.22
Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am J Hum Genet (1992) 1.07
Retinal changes associated with neurofibromatosis 2. Trans Am Ophthalmol Soc (1995) 0.97
Functional analysis of the neurofibromatosis type 2 protein by means of disease-causing point mutations. Am J Hum Genet (2000) 0.94
Ocular fundus in neurofibromatosis type 2. Br J Ophthalmol (1993) 0.90
Lens opacities in neurofibromatosis 2: further significant correlations. Br J Ophthalmol (1993) 0.88
Optimizing biologically targeted clinical trials for neurofibromatosis. Expert Opin Investig Drugs (2013) 0.88
Clinical and genetic patterns of neurofibromatosis 1 and 2. Br J Ophthalmol (1993) 0.87
Neurofibromatosis type 2 protein co-localizes with elements of the cytoskeleton. Am J Pathol (1995) 0.82
Loss of heterozygosity for the NF2 gene in retinal and optic nerve lesions of patients with neurofibromatosis 2. J Pathol (2002) 0.81
Neurofibromatosis 2 leads to choroidal hyperfluorescence in fluorescein angiography. Graefes Arch Clin Exp Ophthalmol (2006) 0.75
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 6.29
A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell (2001) 5.76
Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16. Nature (1995) 4.78
Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. Mol Cell Biol (1996) 4.67
Malondialdehyde alteration of low density lipoproteins leads to cholesteryl ester accumulation in human monocyte-macrophages. Proc Natl Acad Sci U S A (1980) 4.66
Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXR alpha. Proc Natl Acad Sci U S A (2000) 4.58
Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. Mol Cell Biol (1997) 4.36
Atherosclerosis: basic mechanisms. Oxidation, inflammation, and genetics. Circulation (1995) 3.82
Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med (1992) 3.30
Initial clinical experience with intraaortic balloon pumping in cardiogenic shock. JAMA (1968) 3.15
Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. A transcriptional role for specific oxysterols. J Biol Chem (2000) 2.95
Central neurofibromatosis with bilateral acoustic neuroma: genetic, clinical and biochemical distinctions from peripheral neurofibromatosis. Neurology (1980) 2.77
The Yin and Yang of oxidation in the development of the fatty streak. A review based on the 1994 George Lyman Duff Memorial Lecture. Arterioscler Thromb Vasc Biol (1996) 2.56
CDK6 (PLSTIRE) and CDK4 (PSK-J3) are a distinct subset of the cyclin-dependent kinases that associate with cyclin D1. Oncogene (1994) 2.55
Parkinson's disease in 65 pairs of twins and in a set of quadruplets. Neurology (1983) 2.47
Identification of glycerol-3-phosphate acyltransferase as an adipocyte determination and differentiation factor 1- and sterol regulatory element-binding protein-responsive gene. J Biol Chem (1997) 2.36
NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med (1990) 2.31
Monoclonal antibodies to human erythrocytes. Eur J Immunol (1982) 2.24
Elucidation of the deficiency in two yeast coenzyme Q mutants. Characterization of the structural gene encoding hexaprenyl pyrophosphate synthetase. J Biol Chem (1990) 2.19
A human-hybridoma system based on a fast-growing mutant of the ARH-77 plasma cell leukemia-derived line. Eur J Immunol (1982) 2.17
Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). N Engl J Med (1988) 2.16
Specificity of receptor-mediated recognition of malondialdehyde-modified low density lipoproteins. Proc Natl Acad Sci U S A (1982) 2.04
Absence of cyclin D/cdk complexes in cells lacking functional retinoblastoma protein. Oncogene (1994) 1.99
Von Hippel-Lindau disease: clinical and pathological manifestations in nine families with 50 affected members. Arch Intern Med (1976) 1.97
Gilles de la Tourette's syndrome: clinical, genetic, psychologic, and biochemical aspects in 21 selected families. Neurology (1977) 1.97
The metabolism of native and malondialdehyde-altered low density lipoproteins by human monocyte-macrophages. J Lipid Res (1981) 1.97
Attitudes of patients and their relatives to Huntington's disease. J Med Genet (1975) 1.96
The torsion dystonias: literature review and genetic and clinical studies. Neurology (1970) 1.91
Cyclin E associates with BAF155 and BRG1, components of the mammalian SWI-SNF complex, and alters the ability of BRG1 to induce growth arrest. Mol Cell Biol (1999) 1.91
Complex structure and regulation of the P16 (MTS1) locus. Cancer Res (1995) 1.87
Spectral karyotyping suggests additional subsets of colorectal cancers characterized by pattern of chromosome rearrangement. Proc Natl Acad Sci U S A (2001) 1.85
Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. Am J Med Genet (1994) 1.84
Effect of site-directed mutagenesis of conserved aspartate and arginine residues upon farnesyl diphosphate synthase activity. J Biol Chem (1993) 1.83
Significance of cerebellar tonsillar position on MR. AJNR Am J Neuroradiol (1986) 1.80
Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem (2000) 1.75
Factors regulating the activities of the low density lipoprotein receptor and the scavenger receptor on human monocyte-macrophages. J Lipid Res (1981) 1.73
Sterol regulatory element binding protein binds to a cis element in the promoter of the farnesyl diphosphate synthase gene. Proc Natl Acad Sci U S A (1996) 1.71
Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. Am J Hum Genet (1996) 1.70
Monoclonal antibodies to the human mammary gland. I. Distribution of determinants in non-neoplastic mammary and extra mammary tissues. Virchows Arch A Pathol Anat Histol (1982) 1.68
Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism. Oncogene (1999) 1.67
Ameloblastic carcinoma: a clinicopathologic study and assessment of eight cases. Oral Surg Oral Med Oral Pathol (1987) 1.66
Farnesoid X-activated receptor induces apolipoprotein C-II transcription: a molecular mechanism linking plasma triglyceride levels to bile acids. Mol Endocrinol (2001) 1.66
Gilles de la Tourette syndrome: clinical and family study of 50 cases. Ann Neurol (1980) 1.59
COQ2 is a candidate for the structural gene encoding para-hydroxybenzoate:polyprenyltransferase. J Biol Chem (1992) 1.57
Vestibular schwannoma (acoustic neuroma). Consensus development conference. Neurosurgery (1992) 1.55
The role of lipoproteins and receptor-mediated endocytosis in the transport of bacterial lipopolysaccharide. Proc Natl Acad Sci U S A (1986) 1.54
Iron chelation with desferrioxamine B in adults with asymptomatic Plasmodium falciparum parasitemia. Blood (1992) 1.53
Characterization of the human ABCG1 gene: liver X receptor activates an internal promoter that produces a novel transcript encoding an alternative form of the protein. J Biol Chem (2001) 1.53
Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. Am J Hum Genet (1996) 1.52
Mevalonolactone inhibits the rate of synthesis and enhances the rate of degradation of 3-hydroxy-3-methylglutaryl coenzyme A reductase in rat hepatocytes. J Biol Chem (1983) 1.51
In vivo demonstration of the circadian thythm of cholesterol biosynthesis in the liver and intestine of the rat. J Lipid Res (1972) 1.50
Identification of conserved cis-elements and transcription factors required for sterol-regulated transcription of stearoyl-CoA desaturase 1 and 2. J Biol Chem (1999) 1.47
Molecular cloning and sequence of a cholesterol-repressible enzyme related to prenyltransferase in the isoprene biosynthetic pathway. Mol Cell Biol (1987) 1.46
Necrotizing sialometaplasia: literature review and case reports. J Am Dent Assoc (1996) 1.45
Alterations in the rates of synthesis and degradation of rat liver 3-hydroxy-3-methylglutaryl coenzyme A reductase produced by cholestyramine and mevinolin. J Biol Chem (1983) 1.43
Heterogeneous expression of cell-surface antigens in normal epithelia and their tumours, revealed by monoclonal antibodies. Br J Cancer (1985) 1.42
Monoclonal antibodies that bind to the human erythrocyte-membrane glycoproteins glycophorin A and Band 3 [proceedings]. Biochem Soc Trans (1980) 1.42
Separation of and cholesterol synthesis by human lymphocytes and monocytes. J Lipid Res (1979) 1.40
A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor. Cell (1993) 1.38
Molecular cytogenetic analysis of breast cancer cell lines. Br J Cancer (2000) 1.36
Definition of dystonia and classification of the dystonic states. Adv Neurol (1976) 1.36
Properties of purified rat hepatic 3-hydroxy-3-methylglutaryl coenzyme A reductase and regulation of enzyme activity. J Biol Chem (1980) 1.35
Effects of site-directed mutagenesis of the highly conserved aspartate residues in domain II of farnesyl diphosphate synthase activity. J Biol Chem (1992) 1.35
Central neurofibromatosis with bilateral acoustic neuroma. Adv Neurol (1981) 1.34
Familial motor neuron disease. Evidence for at least three different types. Neurology (1976) 1.34
Binding and recognition of GATATC target sequences by the EcoRV restriction endonuclease: a study using fluorescent oligonucleotides and fluorescence polarization. Biochemistry (2001) 1.33
Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol (2000) 1.33
Properties of aqueous dispersions of phospholipid and cholesterol. Eur J Biochem (1968) 1.32
Inactivation of bacteriophage T7 by mono- and difunctional sulphur mustards in relation to cross-linking and depurination of bacteriophage DNA. J Mol Biol (1969) 1.32
Deletion and altered regulation of p16INK4a and p15INK4b in undifferentiated mouse skin tumors. Cancer Res (1995) 1.32
Control of 3-hydroxy-3-methylglutaryl coenzyme A reductase by endogenously synthesized sterols in vitro and in vivo. J Biol Chem (1977) 1.30
Continuous lumbar epidural analgesia using bupivicaine: a study of the fetus and newborn child. J Obstet Gynaecol Br Commonw (1971) 1.29
Identification of farnesol as the non-sterol derivative of mevalonic acid required for the accelerated degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. J Biol Chem (1994) 1.29
Growth retardation in asthmatic children treated with inhaled beclomethasone dipropionate. Lancet (1988) 1.29
Wnt-4 expression induces a pregnancy-like growth pattern in reconstituted mammary glands in virgin mice. Dev Biol (1995) 1.28
Superior intelligence in recessively inherited torsion dystonia. Lancet (1970) 1.28
Accumulation of p16INK4a in mouse fibroblasts as a function of replicative senescence and not of retinoblastoma gene status. Oncogene (1997) 1.27
Impaired mammary gland development in Cyl-1(-/-) mice during pregnancy and lactation is epithelial cell autonomous. Dev Biol (1999) 1.27
Multiple sclerosis in twins. Neurology (1980) 1.26
Synergistic binding of sterol regulatory element-binding protein and NF-Y to the farnesyl diphosphate synthase promoter is critical for sterol-regulated expression of the gene. J Biol Chem (1996) 1.26
Localization of 3-hydroxy-3-methylglutaryl CoA reductase and 3-hydroxy-3-methylglutaryl CoA synthase in the rat liver and intestine is affected by cholestyramine and mevinolin. J Lipid Res (1988) 1.24
Eye findings in bilateral acoustic (central) neurofibromatosis: association with presenile lens opacities and cataracts but absence of Lisch nodules. N Engl J Med (1986) 1.21
Murine PGK-1 promoter drives widespread but not uniform expression in transgenic mice. Dev Dyn (1994) 1.21
Determination of mevalonate in blood plasma in man and rat. Mevalonate "tolerance" tests in man. J Lipid Res (1979) 1.20
The low concentration of macroglobulin antibodies in peripheral lymph. Immunology (1969) 1.19
Environmental-occupational risk factors and familial associations in multiple system atrophy: a preliminary investigation. Clin Auton Res (1991) 1.19
The low concordance rate for Parkinson's disease in twins: a possible explanation. Neurology (1984) 1.18
Mutational analysis of patients with neurofibromatosis 2. Am J Hum Genet (1994) 1.17
Bifrontal decompressive craniectomy in the management of posttraumatic intracranial hypertension. Br J Neurosurg (2001) 1.16
Reverse genetic analysis of Caenorhabditis elegans presenilins reveals redundant but unequal roles for sel-12 and hop-1 in Notch-pathway signaling. Proc Natl Acad Sci U S A (1999) 1.14
Diurnal rhythm of rat liver mRNAs encoding 3-hydroxy-3-methylglutaryl coenzyme A reductase. Correlation of functional and total mRNA levels with enzyme activity and protein. J Biol Chem (1984) 1.14
HLA associations and ancestry in Vogt-Koyanagi-Harada disease and sympathetic ophthalmia. Ophthalmology (1990) 1.13
Gilles de la Tourette syndrome: clinical and genetic studies in a midwestern city. Neurology (1978) 1.12
Synergistic activation of transcription by nuclear factor Y and sterol regulatory element binding protein. J Lipid Res (1998) 1.12
Transcriptional activation of the stearoyl-CoA desaturase 2 gene by sterol regulatory element-binding protein/adipocyte determination and differentiation factor 1. J Biol Chem (1998) 1.12
Retroviral expression of Wnt-1 and Wnt-7b produces different effects in mouse mammary epithelium. J Cell Sci (2000) 1.12
Genetics, geography and intelligence in the torsion dystonias. Birth Defects Orig Artic Ser (1971) 1.11
Elevated plasma dopamine- -hydroxylase activity in autosomal dominant torsion dystonia. N Engl J Med (1973) 1.10